Arecor Therapeutics plc announced a research collaboration with Medtronic plc to develop a novel, high concentration, thermostable insulin for use by Medtronic's Diabetes business in a next-generation implantable pump. This new insulin has the potential to bring significant advancements in the current insulin treatment options for a small population of patients who have limited options for controlling their diabetes with traditional therapy. This collaboration has the potential to allow for the continued care of these patients with an insulin that may minimise the need for pump maintenance interventions and expand the utility for physicians, whilst saving healthcare costs.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
144 GBX | +9.89% | +5.46% | -21.12% |
05-16 | EARNINGS AND TRADING: Michelmersh continues with positive order intake | AN |
05-16 | Transcript : Arecor Therapeutics plc, 2023 Earnings Call, May 16, 2024 |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
144 GBX | +9.89% | +5.46% | 50.98M | ||
85.92 USD | +0.33% | +3.72% | 114B | ||
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.12% | 50.98M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- AREC Stock
- News Arecor Therapeutics plc
- Arecor and Medtronic Diabetes Collaboration